ProKidney (MEX:PROK) Net Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. ProKidney's Net Income for the three months ended in Jun. 2024 was MXN-229.11 Mil. ProKidney's Revenue for the three months ended in Jun. 2024 was MXN0.00 Mil. Therefore, ProKidney's net margin for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for ProKidney's Net Margin % or its related term are showing as below:

MEX:PROK's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -141.49
* Ranked among companies with meaningful Net Margin % only.

ProKidney Net Margin % Historical Data

The historical data trend for ProKidney's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Net Margin % Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Net Margin %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of ProKidney's Net Margin %

For the Biotechnology subindustry, ProKidney's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProKidney's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's Net Margin % distribution charts can be found below:

* The bar in red indicates where ProKidney's Net Margin % falls into.

ProKidney Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ProKidney's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-602.043	/	0
	=	%

ProKidney's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin	=	Net Income (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-229.111	/	0
	=	%

ProKidney (MEX:PROK) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

ProKidney Net Margin % Related Terms

Thank you for viewing the detailed overview of ProKidney's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

PROK:USA

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.